10月15日，美年健康涨5%，截至发稿，报5.46元/股，成交5.29亿元，换手率2.57%，总市值213.72亿 元。 资料显示，美年大健康产业控股股份有限公司位于上海市静安区灵石路697号健康智谷9号楼三楼，成立 日期1991年1月22日，上市日期2005年5月18日，公司主营业务涉及健康体检、健康管理业务。主营业务 收入构成为：体检服务95.67%，其他服务4.33%。 从基金十大重仓股角度 国泰大健康股票A（001645）基金经理为徐治彪。 截至发稿，徐治彪累计任职时间10年60天，现任基金资产总规模35.72亿元，任职期间最佳基金回报 158%， 任职期间最差基金回报-27.38%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，国泰基金旗下1只基金重仓美年健康。国泰大健康股票A（001645）二季度减持269.55万股， 持有股数493.32万股，占基金净值比例为7.29%，位居第四大重仓股。根据测算，今日浮盈赚取约 128.2 ...

Core Points - The company announced the election of Mr. Xu Tao as the employee representative director of the ninth board of directors during the employee representative assembly held on October 14, 2025 [2] Summary by Category - **Company Announcement** - The company held an employee representative assembly on October 14, 2025, where Mr. Xu Tao was elected as the employee representative director [2]

北京商报讯（记者 王寅浩 实习记者 宋雨盈）10月14日，美年健康发布公告称，因工作需要，徐涛申请 辞去公司第九届董事会非职工代表董事及董事会下属战略委员会、提名委员会委员职务。辞职后，徐涛 将继续在公司担任总裁职务，并将在公司职工代表大会选举其为职工代表董事后履行相关职责。 ...

证券代码：002044 证券简称：美年健康 公告编号：2025-073 美年大健康产业控股股份有限公司 二、职工代表董事选举情况 根据《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深圳证券 交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律法规、 规范性文件以及《公司章程》的有关规定，公司于 2025 年 10 月 14 日召开了职工 代表大会，经全体与会职工代表表决，选举徐涛先生担任公司第九届董事会职工 代表董事，与经公司股东大会选举产生的第九届董事会非职工代表董事共同组成 公司第九届董事会，任期自本次职工代表大会选举通过之日起至公司第九届董事 会任期届满之日止。 徐涛先生当选职工代表董事后，公司第九届董事会中兼任公司高级管理人员 以及由职工代表担任的董事人数总计未超过公司董事总数的二分之一，符合相关 法律法规的要求。 三、董事会专门委员会委员选举情况 关于董事调整暨选举职工代表董事的公告 2025 年 10 月 14 日，公司召开第九届董事会第十四次（临时）会议，经全体 董事审议，一致同意选举徐涛先生担任公司第九届董事会下属战略委员会、提名 委员会委员职务，任期自本次董事会审议 ...

证券代码：002044 证券简称：美年健康 公告编号：2025-072 美年大健康产业控股股份有限公司 2025 年第二次临时股东大会决议公告 1、会议召开的时间 （1）现场会议召开时间：2025 年 10 月 14 日（星期二）下午 14:50 （2）网络投票时间为：2025 年 10 月 14 日（星期二）9:15-15:00 1）通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 10 月 14 日 9:15-9:25，9:30-11:30 和 13:00-15:00； 2）通过互联网投票系统进行网络投票的具体时间为 2025 年 10 月 14 日 9:15-15:00 的任意时间。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无否决或修改提案的情况，无涉及变更前次股东大会决议的 情况。 2、本次股东大会审议的全部议案已对中小投资者（指除上市公司的董事、监 事、高级管理人员以及单独或者合计持有上市公司5%以上股份的股东以外的股东） 的表决单独计票。 一、会议召开和出席情况 （一）会议召开情况 2、现场会议召 ...

证券代码：002044 证券简称：美年健康 公告编号：2025-074 美年大健康产业控股股份有限公司 二、董事会会议审议情况 第九届董事会第十四次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 美年大健康产业控股股份有限公司（以下简称"公司"）第九届董事会第十四 次（临时）会议于 2025 年 9 月 28 日以电子发送等形式发出会议通知，会议于 2025 年 10 月 14 日下午 17 时以书面审议方式召开。应出席本次会议的董事为 9 名，实 际出席会议的董事为 9 名。本次会议的出席人数、召开表决程序、议事内容均符 合《中华人民共和国公司法》《公司章程》等有关规定。 1、审议并通过《关于选举代表公司执行公司事务的董事的议案》 表决结果：赞成 9 票，反对 0 票，弃权 0 票。 2、审议并通过《关于选举董事会各专门委员会成员及召集人的议案》 根据《中华人民共和国公司法》及《公司章程》等有关规定，同意公司选举 董事长俞熔先生为代表公司执行公司事务的董事，并担任法定代表人，任期自本 次董事会审议通过之日起至第九 ...

Group 1 - The core point of the article is that Meien Health announced the convening of its 14th temporary meeting of the 9th Board of Directors on October 14, 2025, to review various proposals, including the election of directors to manage company affairs [1] - For the first half of 2025, Meien Health's revenue composition shows that the medical industry accounted for 99.37% of total revenue, while other businesses contributed 0.63% [1] - As of the time of reporting, Meien Health has a market capitalization of 20.4 billion yuan [1]

北京市天元律师事务所 关于美年大健康产业控股股份有限公司 2025 年第二次临时股东大会的 法律意见 京天股字（2025）第 638 号 致：美年大健康产业控股股份有限公司 美年大健康产业控股股份有限公司（以下简称"公司"）2025 年第二次临时股 东大会（以下简称"本次股东大会"）采用现场投票与网络投票相结合的方式召开， 现场会议于 2025 年 10 月 14 日 14:50 在上海市静安区灵石路 697 号健康智谷 9 号 楼公司会议室召开。北京市天元律师事务所（以下简称"本所"）接受公司聘任，指 派本所律师参加本次股东大会现场会议，并根据《中华人民共和国公司法》、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以 下简称"《股东会规则》"）以及《美年大健康产业控股股份有限公司章程》（以下 简称"《公司章程》"）等有关规定，就本次股东大会的召集、召开程序、出席会议 人员的资格、召集人资格、会议表决程序和表决结果等有关事宜出具本法律意见。 为出具本法律意见，本所律师审查了《美年大健康产业控股股份有限公司第九 届董事会第十三次（临时）会议决议公告》《美年大健康产业控股股份有限公 ...

Investment Rating - The report maintains a strong confidence in the pharmaceutical sector's potential for a reversal in 2025, particularly focusing on innovative drugs and the recovery of left-side sectors as the biggest investment opportunities for the year [5][14]. Core Insights - The innovative drug sector is expected to continue its upward trend, with BD (business development) activities anticipated to catalyze market movements. The upcoming ESMO conference (October 17-21) is highlighted as a key event for clinical data disclosures from domestic innovative drug companies [2][13]. - The report emphasizes the importance of recent Nobel Prize discoveries related to peripheral immune tolerance, which are relevant to the development of new therapies in oncology and autoimmune diseases. This underscores the significance of innovation in these fields [40][50]. - The report notes that the CXO industry in China is entering a recovery phase, with improvements expected in industry orders, capacity utilization, and performance metrics due to enhanced domestic investment and financing data [2][5]. Summary by Sections Innovative Drugs - The innovative drug sector has seen a recent pullback, but the long-term upward trend remains intact. The report suggests that the market is awaiting further BD catalysts and highlights the importance of upcoming clinical data from the ESMO conference [2][13]. - The report indicates that the overall sentiment in the innovative drug sector is still positive, with a focus on potential breakthroughs in cancer and autoimmune therapies following the recent Nobel Prize discoveries [40][50]. Biologics - Novo Nordisk announced an agreement to acquire Akero for $4.7 billion, with Akero's FGF21 analog EFX showing promise as a leading therapy for metabolic dysfunction-related fatty liver disease (MASH) [3][51]. - The report suggests that EFX is the only drug in Phase 2 trials demonstrating significant fibrosis regression in F4 patients, highlighting the need for continued attention to developments in this area [51][57]. Medical Devices - The commercialization of innovative products is accelerating, with domestic replacements making significant progress. For instance, MicroPort's Tumi laparoscopic surgical robot has surpassed 100 global orders and is leading the domestic market share [4][58]. - The report notes that the Tumi robot has received market access in over 60 countries and regions, with a strong presence in high-end markets such as Europe [60][62]. Traditional Chinese Medicine - There has been a continuous increase in new drug IND and NDA applications for traditional Chinese medicine, with 92 new IND applications and 42 NDA applications reported in the first nine months of 2025 [3][64]. - The report highlights ongoing policy support for traditional Chinese medicine, which is expected to drive further innovation and development in this sector [64][65].

Group 1 - The company, Meinian Health Industry Holdings Co., Ltd., will hold its second extraordinary general meeting of shareholders in 2025 on October 14, 2025, at 14:50 in Shanghai [2][4] - The meeting will combine on-site voting and online voting, with specific time slots for each voting method [5][6][7] - The record date for shareholders to attend the meeting is October 9, 2025 [8] Group 2 - The meeting will be convened by the company's board of directors, and the convening process complies with relevant laws and regulations [3] - Shareholders can appoint proxies to attend the meeting, and the proxies do not need to be shareholders of the company [10] - The meeting will discuss proposals that have been approved by the board of directors, with specific voting requirements for special resolutions [11] Group 3 - The company has provided guarantees for its subsidiaries, with a total guarantee limit of up to RMB 4.9 billion for the year 2025 [29] - Recent guarantees include a maximum liability of RMB 100 million for Meinian Health Industry (Group) Co., Ltd. and RMB 10 million for Chengdu Jinjiang Meinian Health [30][31] - The company has signed various guarantee contracts with banks, including Jiangsu Bank, Nanjing Bank, and others, with specific amounts and terms outlined [55][59][62] Group 4 - As of October 9, 2025, the total external guarantee balance provided by the company and its subsidiaries is RMB 36.97 billion, accounting for 46.72% of the company's audited net assets for 2024 [66] - There have been no overdue guarantees or legal disputes related to the guarantees provided by the company [66]